After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.